Hepatitis B Country Profile

**Country Demographics**

- **Total Population (2018)**: 6,956,071
- **Urban Population (% of total, 2018)**: 61.6%
- **Health expenditure per capita (US$, 2016)**: $327.2
- **Health expenditure, total (% of GDP, 2016)**: 8.0%
- **Total births (2013)**: 162,000
- **Surviving Infants (2013)**: 157,000
- **Life expectancy at birth (years, 2017)**: 73.2 years
- **Number of districts (2013)**: 79

**HBsAg Prevalence**

- Pre-vaccine HBsAg+ (%): 2.2%

**Liver Cancer as Cause of Cancer Death (in Men)**

- **Year**: 2018
- **Ranking**: 8

**2018 Country Comparison in Americas Region (35 Countries)**

<table>
<thead>
<tr>
<th></th>
<th>Paraguay</th>
<th>Number of countries with reported coverage</th>
<th>Highest reported coverage in AMR</th>
<th>Lowest reported coverage in AMR</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3</td>
<td>88%</td>
<td>35</td>
<td>99% (Cuba, Trinidad and Tobago)</td>
<td>55% (Mexico)</td>
</tr>
<tr>
<td>HepB BD</td>
<td>NR</td>
<td>22</td>
<td>99% (Cuba)</td>
<td>17% (Saint Lucia)</td>
</tr>
</tbody>
</table>

**Hepatitis B Immunization Coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>HepB3</th>
<th>HepB BD</th>
<th>DTP3</th>
<th>BCG</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>NR</td>
<td>NR</td>
<td>86%</td>
<td>85%</td>
</tr>
<tr>
<td>2001</td>
<td>NR</td>
<td>NR</td>
<td>90%</td>
<td>86%</td>
</tr>
<tr>
<td>2002</td>
<td>NR</td>
<td>NR</td>
<td>92%</td>
<td>92%</td>
</tr>
<tr>
<td>2003</td>
<td>NR</td>
<td>NR</td>
<td>92%</td>
<td>92%</td>
</tr>
<tr>
<td>2004</td>
<td>NR</td>
<td>NR</td>
<td>86%</td>
<td>92%</td>
</tr>
<tr>
<td>2005</td>
<td>NR</td>
<td>NR</td>
<td>87%</td>
<td>98%</td>
</tr>
<tr>
<td>2006</td>
<td>NR</td>
<td>NR</td>
<td>85%</td>
<td>98%</td>
</tr>
<tr>
<td>2007</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>98%</td>
</tr>
<tr>
<td>2008</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2009</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2010</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2011</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2012</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2013</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2014</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2015</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2016</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2017</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
<tr>
<td>2018</td>
<td>NR</td>
<td>NR</td>
<td>91%</td>
<td>94%</td>
</tr>
</tbody>
</table>

**Paraguay: HepB3 vs. DTP3**

- HepB3
- DTP3

**Abbreviations**: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database¹, WHO Immunization Summary: A statistical reference containing data through 2013², WHO Public Health Significance, Targets, Strategies: HBV country profiles³, Global Cancer Observatory: Cancer Today-IARC⁴, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates⁵